Clinical Trials Logo

Immune-related Adverse Event clinical trials

View clinical trials related to Immune-related Adverse Event.

Filter by:

NCT ID: NCT05663775 Not yet recruiting - Diarrhea Clinical Trials

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

IMPACT 1
Start date: April 2023
Phase: Phase 2
Study type: Interventional

The study team's principal interest is to address the question, "Will prophylactic treatment with mesalamine reduce the incidence and severity of immune-related diarrhea occurring secondarily to treatment with ipi/nivo?"

NCT ID: NCT05544292 Recruiting - Clinical trials for Immune-related Adverse Event

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors

RIMRA
Start date: March 5, 2018
Phase:
Study type: Observational

RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.

NCT ID: NCT04305145 Recruiting - Melanoma Stage IV Clinical Trials

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: - How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? - How many patients treated with steroids experience steroid-free disease resolution after 7 weeks?

NCT ID: NCT03948724 Active, not recruiting - Clinical trials for Head and Neck Cancer

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

EDHITO
Start date: December 11, 2019
Phase: N/A
Study type: Interventional

The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI